Global Cannabis Laws in 2026: A Fragmented Legal Landscape

Where is cannabis legal worldwide? An overview of the situation in 2026.
Global cannabis policy in 2026 will encompass four broad categories. First, there is strict prohibition, which remains in effect in large parts of Asia, the Middle East, and sub-Saharan Africa, and in some cases prescribes draconian penalties.

Second, decriminalization, where consumption and possession of small quantities remain prohibited but are, in practice, treated as minor offenses or not prosecuted at all. Classic examples of this model are Portugal, the Netherlands, Belgium, Spain, and numerous Latin American countries.

Third, there are partially legalized countries that permit home cultivation, personal use, or non-commercial procurement through associations without creating an open commercial market. Germany and Malta have been part of this category since 2024, and the Czech Republic since 2026, along with Luxembourg, South Africa, and Georgia (with some restrictions).

Fourth, there are fully commercially regulated markets. Currently, only Canada and Uruguay, as well as 24 US states, the District of Columbia, and the Australian Capital Territory, operate at this highest level.

Alongside this, there is a medical pathway that is considerably broader. Australia, Argentina, Brazil, Israel, the UK, most EU member states, and a growing number of Asian and African countries allow doctors to prescribe cannabis as medicine. MJBizDaily’s industry analysis counted around fifty countries with formal regulations for medical cannabis at the beginning of 2026.

Patients in Germany have been aware of this access route since 2017, as described in detail in the 2026 Patient Guide . Internationally, however, the picture is heterogeneous, as some countries restrict prescriptions to a few indications, while others limit them to finished medicinal products without the release of the flower.

The discrepancy between formal legal regulations and actual practice remains striking. In Spain, thousands of cannabis social clubs operate in a legal gray area, without any nationwide regulation. In the US, money flows into an industry whose products are still considered illegal drugs at the federal level. And in Thailand, the political climate shifted in 2024 from a pro-legalization stance to renewed restrictions. This patchwork nature is no longer a transitional phenomenon, but rather defines international cannabis policy in the second half of the 2020s.

North America: From pioneer Canada to the US states

In 2018, Canada became the first G7 country to commercially legalize cannabis. Eight years later, the market has consolidated, a wave of early excesses and stock market flops is behind the industry, and the provinces are experimenting with different distribution models, from state monopolies in Quebec to private licensed distributors in Ontario. Canada’s role as an exporter is particularly interesting for Germany.

According to data from the Federal Institute for Drugs and Medical Devices, 62 percent of all medical cannabis flowers imported into Germany now come from Canada, significantly ahead of Portugal, North Macedonia, and Australia. This means that legalization is no longer just a socio-political issue, but a tangible foreign trade question.

In contrast, the United States has provided a prime example of legal inconsistency for years. Twenty-four states and the District of Columbia have legalized cannabis for adults, forty states permit medical use, and industry revenue exceeded thirty billion US dollars in 2025. At the federal level, however, cannabis remained Schedule I for a long time, meaning it was pharmacologically equated with heroin. In April 2026, the Department of Justice took a partial step that electrified the industry.

At the direction of the DEA, FDA-approved cannabis medicines and products from state-licensed medical programs were reclassified as Schedule III, which provides tax and research-related relief. The originally planned reclassification of all cannabis to Schedule III will be debated in a series of hearings beginning in late June 2026. Recreational cannabis remains illegal at the federal level for the time being, which continues to complicate banking, trademark protection, and tax practices.

Mexico, for its part, has been in a peculiar limbo for years. The Supreme Court declared the cannabis prohibition unconstitutional back in 2021, yet comprehensive parliamentary legislation is still lacking. Consumption and personal cultivation for adults are de facto legal; a legal market does not exist. The contrast between the legal situation and political reality demonstrates how difficult reforms are to implement in an environment shaped by the logic of the drug war.

Europe between Pillar 2, pilot projects and coffee shops

Europe will be the world’s most exciting cannabis policy laboratory in 2026. With Germany, Malta, Luxembourg, and, since January, the Czech Republic, there are four EU member states where adults can possess, cultivate, and obtain cannabis without penalty through club-based structures. Add to that Switzerland and individual Dutch cities with commercial pilot projects, Spain’s semi-legal social clubs, and Portugal’s decriminalization established in 2001. This density of models provides comparable data like nowhere else in the world.

The German Cannabis Act (CanG) has permitted the personal cultivation of up to three plants and the purchase of cannabis through cultivation associations since April 1, 2024. The results of the first two years are mixed, as documented in the article summarizing the Cannabis Act . Police statistics and addiction research report either relief or concern, depending on the indicator; the black market has not disappeared, but has shrunk noticeably in some regions.

The economically crucial step, the second commercial pillar with regional pilot projects , has been stuck in inter-ministerial coordination for two years. The Federal Office for Agriculture and Food has received 60 applications, 34 of which are genuine pilot projects, but a concrete sales launch date for 2026 has not yet been set for any region.

The Czech Republic implemented its own reform on January 1, 2026. Adults aged 21 and over are permitted to cultivate up to three plants, possess 100 grams at home, and 25 grams in public. A commercial market is explicitly not part of this initial reform but is planned for a second phase once EU legal hurdles have been cleared. Switzerland is taking a different approach.

Since 2023, the Swiss Confederation has been testing regulated sales to registered consumers through pilot projects in Zurich, Basel, Bern, and Lausanne. The Zurich project, Züri Can, has been extended until 2028 , and other municipalities have joined the initiative. In February 2025, the Federal Council also submitted a draft law for public consultation, which aims to establish a state-controlled cannabis market. If it passes Parliament and the people, Switzerland would become the fourth European country, after Malta, Luxembourg, and Germany, to implement explicit adult-only regulations.

The Netherlands, for decades synonymous with tolerated cannabis use, is undergoing a two-pronged transformation. On the one hand, the coffeeshop pilot project is underway , with around 80 establishments selling exclusively legally produced cannabis, thus closing the decades-old backdoor problem for the first time. On the other hand, Amsterdam has closed coffeeshops in the city center to tourists, initiating a change of course that is more a matter of city marketing than drug policy.

In Spain, social clubs are flourishing, modeled on the Catalan example, without any nationwide regulation. Portugal is sticking to its pragmatic decriminalization policy and has the lowest drug-related death rate in Western Europe. Great Britain remains restrictive but has created a formally legal access route to medical cannabis through specialized clinics, which are estimated to be used by over 50,000 patients.

Latin America and the Caribbean: Uruguay as a pioneer, Mexico on standby

Uruguay legalized cannabis in 2013, long before Canada followed suit. The model is state-centric. Registered users obtain cannabis through pharmacies, cannabis social clubs, or by cultivating it themselves. Economically, the market remained manageable but stable and is now considered proof that even a relatively small state can operate with consistent regulation without causing social upheaval.

Argentina, Chile, Colombia, and Peru have established medical cannabis programs, some with restrictive import regulations, others linked to a legal export market. Colombia has become the third-largest supplier of medical cannabis flowers to Europe, a role that is gradually emancipating the country from its historical entanglement with the illegal drug market.

Brazil has legalized medicinal cannabis since 2015, but commercial home cultivation remains prohibited, and patient organizations complain about bureaucratic hurdles. Costa Rica legalized industrial hemp cultivation in 2022 and is working on a medicinal program.

In the Caribbean, Jamaica is the most prominent player; there, cannabis is considered part of Rastafarian religious practice, small quantities are decriminalized, and the island nation also exports medicinal cannabis to Europe. Saint Vincent and the Grenadines and Barbados are pursuing similar approaches, treating cannabis as both an economic factor and a cultural heritage. Mexico remains the special case, its reform potential touted for years but never realized.

Africa, Asia and Oceania: Between legalization and backlash

In 2018, South Africa took an unexpected step for the continent. The Constitutional Court declared the ban on private consumption and cultivation incompatible with the right to privacy. Since then, personal cultivation has been permitted, but a commercial market has yet to materialize.

Lesotho, Malawi, Zambia, Zimbabwe, Morocco, and Rwanda have granted licenses for medicinal and industrial cultivation and are positioning themselves as exporters to the European market, where demand is projected to grow significantly faster than supply by 2026. Morocco, historically Europe’s most important supplier of hashish, established legal cultivation in the Rif Mountains for the first time in 2021 and exported its first certified harvests in 2024.

Asia is showing two seemingly opposing trends. On the one hand, medical cannabis programs are expanding in Israel, Sri Lanka, South Korea, Japan, the Philippines, and Hong Kong, albeit under strict regulations. On the other hand, Thailand has reversed the reform course it began in 2022. The new conservative government announced in 2024 that it would not reclassify cannabis as a narcotic but would strictly control the virtually unregulated market.

Several thousand coffee shops that sprang up across the country after 2022 must obtain licenses or close. The case of Thailand has become a cautionary tale of how quickly reforms can collapse without a robust regulatory framework.

Australia has decriminalized cannabis for adults in its capital region, ACT, while the rest of the country relies on a growing medical program serving over 500,000 patients. New Zealand narrowly failed to decriminalize cannabis in a 2020 referendum but maintains its medical program.

In Japan, long a country with particularly harsh drug policies, the medical use of cannabinoid-based medications has been permitted for the first time since 2024. This move demonstrates that even the strictest Asian drug regimes are gradually becoming more permeable due to pharmaceutical interests and patient pressure.

__

(Featured image by Alessia Kozik via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Hanf-Magazin. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.